Allogene Therapeutics
ALLO
ALLO
208 hedge funds and large institutions have $445M invested in Allogene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 80 increasing their positions, 40 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
21% more funds holding
Funds holding: 172 → 208 (+36)
3.16% more ownership
Funds ownership: 72.38% → 75.54% (+3.2%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
208
Holding in Top 10
2
Calls
$776K
Puts
$373K
Top Buyers
| 1 | +$11.8M | |
| 2 | +$6.34M | |
| 3 | +$5.46M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.35M |
Top Sellers
| 1 | -$10.7M | |
| 2 | -$3.49M | |
| 3 | -$3.32M | |
| 4 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$3.03M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.82M |
